AcquiTrust Exclusive! Rare opportunity to acquire a fully licensed, fully accredited specialty pharmacy platform combining three complementary operations under one transaction: a community retail pharmacy, a closed-door specialty pharmacy holding active 340B contract pharmacy agreements, and an ambulatory infusion suite operating within the same facility.

What makes this platform difficult to replicate:

17 non-resident pharmacy licenses. Multi-state licensure is the single largest barrier to entry in specialty pharmacy. Building this footprint independently takes two to three years of applications, inspections, and fees. It transfers with this transaction, and the current owner will remain engaged to support the transition.

ACHC accreditation under USP 795 and 797 covering sterile, non-sterile, hazardous, and non-hazardous compounding. The facility and clean room are already built, inspected, and accredited. This is a functioning compounding operation, not a plan for one.

Three 340B contract pharmacy agreements, recently executed.

Contract one is live and currently servicing approximately 25 patients per month through an STD clinic, with volume growing.
Contract two goes live in October and represents substantial upside — it serves a federally qualified health center whose commercial BCBS panel alone is approximately 1,500 lives. The health center is dissatisfied with its incumbent pharmacy provider's service levels, and the expectation is exclusive provider status.
Contract three is executed and pending activation.
Ambulatory infusion suite already operating inside the pharmacy, providing a second revenue channel and a natural referral path from the specialty book.

Immediate conversion path to 503A sterile compounding. Because the facility already holds 795/797 ACHC accreditation, the buildout, equipment, and quality systems required for a 503A sterile compounding operation are largely in place. For a buyer targeting the peptide compounding market, the conversion is a matter of registration and process rather than construction and capital.

The opportunity — stated plainly
This platform is being sold on its infrastructure, licensing, and contracted growth pipeline, not on trailing earnings. Current operations are not profitable, and the reason is specific and correctable: the pharmacy is not sourcing medications at optimal acquisition cost. As a result, a meaningful share of scripts carry negative margin and are being routed away to payer mail-order facilities rather than filled in-house.

This is a purchasing and wholesaler-terms problem, not a demand problem. Script volume is present. The infrastructure to fill is present. The licensing to fill across state lines is present. A buyer with an existing GPO relationship, established wholesaler terms, or the working capital to normalize purchasing captures margin on volume that is already walking through the door — plus the volume currently being turned away.

Combined revenue is running at approximately $2.1 million annualized on 2026 results, with combined gross margin at 23%. A buyer bringing acquisition cost in line with market norms for a closed-door 340B operation improves that margin materially on existing volume, before any of the contracted growth is counted.

It is a strategic transition designed to bring in the right partner to accelerate growth. Seller financing flexibility available. Business will be disclosed only upon execution of an NDA and buyer qualification. Offered Exclusively By: AcquiTrust Advisors- Your Advantage in Every Acquisition.